AFP, recognized as a key biomarker in HCC management, has shown renewed significance in predicting treatment outcomes through its dynamic variations, commonly referred to as the “AFP response” (19, 23, 24, 30, 31). The gene discussed is AFP; the disease is hepatocellular carcinoma.